Since the expression levels of AHCY, ACO2, OXCT1, UCP2 and CAP1 were lower in the striatum of HD mouse models and the human leukocytes when compared with their wild-type and the controls respectively, they serve as potential biomarkers to indicate the disease stage or progression not only for animal studies but also for clinical trials. This evidence concerns the gene AHCY and Huntington disease.